Final Analysis of Overall Survival from the Phase 3 Panorama 1 Trial of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma

被引：4

作者：

San-Miguel, Jesus F. ^{[1
]}

Hungria, Vania T. M. ^{[2
]}

Yoon, Sung-Soo ^{[3
]}

Beksac, Meral ^{[4
]}

Dimopoulos, Meletios A. ^{[5
]}

Elghandour, Ashraf ^{[6
]}

Jedrzejczak, Wieslaw W. ^{[7
]}

Guenther, Andreas ^{[8
]}

Nakorn, Thanyaphong Na ^{[9
,10
]}

Siritanaratkul, Noppadol ^{[11
]}

Schlossman, Robert L. ^{[12
]}

Hou, Jian ^{[13
]}

Moreau, Philippe ^{[14
]}

Lonial, Sagar ^{[15
]}

Lee, Jae Hoon ^{[16
]}

Einsele, Hermann ^{[17
]}

Sopala, Monika ^{[18
]}

Bengoudifa, Bourras-Rezki ^{[18
]}

Corrado, Claudia ^{[18
]}

Richardson, Paul G. ^{[12
]}

机构：

[1] Clin Univ Navarra CIMA, Pamplona, Spain

[2] Santa Casa Med Sch, Hematol & Oncol, Sao Paulo, Brazil

[3] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea

[4] Ankara Univ, Fac Med, Dept Hematol, TR-06100 Ankara, Turkey

[5] Univ Athens, Athens 11528, Greece

[6] Univ Alexandria, Qesm Bab Sharqi, Egypt

[7] Med Univ Warsaw, Hematol Oncol & Internal Dis, Warsaw, Poland

[8] Univ Kiel, Kiel, Germany

[9] Chulalongkorn Univ, Bangkok, Thailand

[10] King Chulalongkorn Mem Hosp, Bangkok, Thailand

[11] Mahidol Univ, Dept Pediat & Internal Med, Siriraj Hosp, Bangkok 10700, Thailand

[12] Dana Farber Canc Inst, Boston, MA 02115 USA

[13] Second Mil Med Univ, Changzheng Hosp, Dept Hematol, Myeloma & Lymphoma Ctr, Shanghai, Peoples R China

[14] Nantes Univ Hosp, Dept Hematol, Nantes, France

[15] Emory Univ, Winship Canc Inst, Div BMT, Atlanta, GA 30322 USA

[16] Gachon Univ, Gil Med Ctr, Inchon, South Korea

[17] Univ Hosp Wurzburg, Dept Med 2, Wurzburg, Germany

[18] Novartis Pharma AG, Basel, Switzerland

来源：

BLOOD | 2015年 / 126卷 / 23期

关键词：

D O I：

10.1182/blood.V126.23.3026.3026

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[1] Characterization of the Incidence and Management of Gastrointestinal Toxicity in the Phase 3 Panorama 1 Study of Panobinostat Plus Bortezomib and Dexamethasone Versus Placebo Plus Bortezomib and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma
Richardson, Paul G.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw Wiktor
Guenther, Andreas
Thanyaphong Na Nakorn
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Salwender, Hans
Sopala, Monika
Panneerselvam, Ashok
Redhu, Suman
Corrado, Claudia
Binlich, Florence
San Miguel, Jesus F.
[J]. BLOOD, 2014, 124 (21)
[2] Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial
San-Miguel, Jesus F.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios Athanasios
Elghandour, Ashraf
Jedrzejczak, Wieslaw Wiktor
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Corradini, Paolo
Chuncharunee, Suporn
Lee, Je-Jung
Schlossman, Robert L.
Shelekhova, Tatiana
Yong, Kwee
Tan, Daryl
Numbenjapon, Tontanai
Cavenagh, Jamie D.
Hou, Jian
LeBlanc, Richard
Nahi, Hareth
Qiu, Lugui
Salwender, Hans
Pulini, Stefano
Moreau, Philippe
Warzocha, Krzysztof
White, Darrell
Blade, Joan
Chen, WenMing
de la Rubia, Javier
Gimsing, Peter
Lonial, Sagar
Kaufman, Jonathan L.
Ocio, Enrique M.
Veskovski, Ljupco
Sohn, Sang Kyun
Wang, Ming-Chung
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Corrado, Claudia
Bengoudifa, Bourras-Rezki
Binlich, Florence
Richardson, Paul G.
[J]. LANCET ONCOLOGY, 2014, 15 (11): : 1195 - 1206
[3] ANALYSIS OF OUTCOMES BY RESPONSE FOR PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PHASE 3 PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE
Moreau, P.
San-Miguel, J.
Hungria, V.
Yoon, S. S.
Beksac, M.
Dimopoulos, M.
Elghandour, A.
Jedrzejczak, W.
Guenther, A.
Nakorn, T. Na
Siritanaratkul, N.
Schlossman, R.
Hou, J.
Lonial, S.
Lee, J. H.
Einsele, H.
Sopala, M.
Bengoudifa, B. -R.
Corrado, C.
Richardson, P.
[J]. HAEMATOLOGICA, 2015, 100 : 80 - 81
[4] Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial
San-Miguel, Jesus F.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong N.
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae H.
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Binlich, Florence
Richardson, Paul G.
[J]. LANCET HAEMATOLOGY, 2016, 3 (11): : E506 - E515
[5] Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, doubleblind phase 3 trial (vol 15, pg 1195, 2014)
San Miguel, J. F.
Hungria, V. T. M.
Yoon, S-S
[J]. LANCET ONCOLOGY, 2015, 16 (01): : E6 - E6
[6] Panobinostat plus bortezomib and dexamethasone for relapsed myeloma
Pratt, Guy
[J]. Lancet Haematology, 2016, 3 (11): : E498 - E499
[7] SUBGROUP ANALYSIS BY PRIOR TREATMENT AMONG PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY OF PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE
Einsele, H.
Richardson, P.
Hungria, V.
Yoon, S. S.
Beksac, M.
Dimopoulos, M.
Elghandour, A.
Jedrzejczak, W.
Guenther, A.
Nakorn, T. Na
Siritanaratkul, N.
Schlossman, R.
Hou, J.
Moreau, P.
Lonial, S.
Lee, J. H.
Sopala, M.
Bengoudifa, B. R.
Corrado, C.
San-Miguel, J.
[J]. HAEMATOLOGICA, 2015, 100 : 1 - 1
[8] Panorama 1: A randomized, double-blind, phase 3 study of panobinostat or placebo plus bortezomib and dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Richardson, Paul G.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Corrado, Claudia
San-Miguel, Jesus F.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
[9] Panobinostat plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma who received prior bortezomib and IMiDs: A predefined subgroup analysis of PANORAMA 1.
San Miguel, Jesus F.
Hungria, Vania T. M.
Yoon, Sung-Soo
Beksac, Meral
Dimopoulos, Meletios A.
Elghandour, Ashraf
Jedrzejczak, Wieslaw W.
Guenther, Andreas
Nakorn, Thanyaphong Na
Siritanaratkul, Noppadol
Schlossman, Robert L.
Hou, Jian
Moreau, Philippe
Lonial, Sagar
Lee, Jae Hoon
Einsele, Hermann
Sopala, Monika
Bengoudifa, Bourras-Rezki
Corrado, Claudia
Richardson, Paul G.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
[10] Estimating Utilities for Panobinostat in Combination with Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Relapsed and/or Refractory Multiple Myeloma; Evidence from the Panorama-1 Trial
Majer, Istvan
Krishna, Arun
van de Wetering, Gijs
San-Miguel, Jesus F.
Richardson, Paul G.
[J]. BLOOD, 2015, 126 (23)

← 1 2 3 4 5 →